title: Cytomegalovirus infection and graft rejection in renal transplantation.
abstract: BACKGROUND
  Cytomegalovirus (CMV) infection and CMV disease have been associated with acute and chronic graft rejection. The introduction of the sensitive CMV antigenemia pp65 assay for detection of CMV infection allowed us to study the time course of CMV infection and acute rejection and the long-term outcome in renal transplant recipients with and without a CMV risk constellation.
  
  
  METHODS
  Prospective single center study including 48 renal transplant recipients at risk for CMV infection (donor and/or recipient CMV seropositive) and a control group of 36 CMV seronegative recipients of CMV seronegative kidney donors. Evidence of CMV infection was monitored by the CMV antigenemia pp65 assay every 1 to 2 weeks and compared with the occurrence of acute rejection in the posttransplant period and graft function at 5 years.
  
  
  RESULTS
  CMV infection developed in 83% (40/48) of patients of the CMV risk group within 4 months posttransplant. A total of 18 of patients experienced an acute rejection episode (control group 16/36; P=0.65). In 12/18 CMV infection followed rejection and in three patients antigenemia preceded the diagnosis of rejection. In three patients CMV antigenemia remained negative. Five-year follow up: Patient survival (44/48 vs. 31/36; P=0.48), graft survival (38/48 vs. 27/36; P=0.79), number of patients with at least one acute rejection episode: CMV risk group: 42.1%, control group 51% (P=0.46), serum creatinine: CMV risk group:130 +/- 66 micromol/iter, control group: 126 +/- 37 micromol/ liter (P=0.56), proteinuria: CMV risk group: 0.02 +/- 0.02 g/mmol creatinine, control group: 0.02 +/- 0.02 g/mmol creatinine (P=1.0).
  
  
  CONCLUSIONS
  CMV infection within 4 months posttransplant, as defined by a positive antigenemia assay was not found to be a risk factor for acute graft rejection or chronic graft dysfunction at 5 years.
authors.affiliation: Department of Internal Medicine, University Hospital, Basel, Switzerland.
authors.forename: M J
authors.initials: MJ
authors.lastname: Dickenmann
authors.forename: G
authors.initials: G
authors.lastname: Cathomas
authors.forename: J
authors.initials: J
authors.lastname: Steiger
authors.forename: M J
authors.initials: MJ
authors.lastname: Mihatsch
authors.forename: G
authors.initials: G
authors.lastname: Thiel
authors.forename: M
authors.initials: M
authors.lastname: Tamm
mesh_terms: D000328:Adult; D000368:Aged; D000956:Antigens, Viral / Q000097:blood; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000453:epidemiology; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000382:microbiology*; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D000956:Antigens, Viral